Differences in expression of predictive biomarkers between primary and metastatic non-small cell lung cancer tumors
Monitoring of secondary drug resistance mutations in circulating tumor DNA of patients with advanced ALK positive NSCLC
Liquid biopsy in patients with adenocarcinoma of the lung and its correlation with their tumor tissue molecular profile
Co-amplifications of PD-L1/PD-L2 genes (9p24.1) and PD-L1 protein expression in NSCLC patients
PD-L1 expression in NSCLC
Expression of PD-L1 in lung cancer cells regulates Treg cell differentiation
Proangiogenic effect of peritoneal macrophages from animals with Lewis lung carcinoma
EGFR, KRAS, BRAF, and PI3K mutations and ALK rearrangement in 327 consecutive Spanish non-squamous NSCLC patients
Characterization of chromosomal region 18q in NSCLC KRAS mutant tumors
Prognostic impact of MET mutations in exon 14 and copy number alterations in a series of NSCLC patients
Volatolomic signatures of anaplastic lymphoma kinase gene rearrangement in adenocarcinoma
Expression of Notch 1 and Notch 3 proteins in imprints of NSCLC: Correlation with prognostic factors
Tumor microcirculation based biomarker discovery strategy for non-small cell lung cancer (NSCLC)
Change of mTOR, p6, NBR1 and LC3A/B-I/II in A549 cells treated with graphene oxides
The overexpression of SASH1 stimulates cell death in lung cancer cells
Examination of EXOSC4 as a new prognostic marker and a novel therapeutic avenue in lung adenocarcinoma
Epithelial-to-mesenchymal transition (EMT) is required for resistance to anti-folate chemotherapy in lung cancer
Comparative effectiveness analysis of HSP90 inhibitors in non-small cell lung cancer
Context-dependent role of FGFR4 in lung tumorogenesis
U2AF1 (S34F) mutation leads to altered global splicing patterns and dysregulation of cell cycle and mitosis
Increased schedule-dependent efficiency of pemetrexed–cisplatin combination therapy eliminates resistant lung cancer stem-like cells associated with EMT
Prolonged pemetrexed pretreatment increases efficiency of ionizing radiation combination therapy and correlates with the persistence of treatment-induced DNA damage in lung cancer cells
CDCA3 regulates the cell cycle and modulates cisplatin sensitivity in non-small cell lung cancer
Autophagy in early stage NSCLC – prognostic significance of the autophagy markers p62 and LC3B
Characteristics of circulating tumor cells (CTCs) in patients with lung cancer
The impact of hypolipidemic drugs on course and prognosis of lung cancer
Different genetic profiling in lung adenocarcinoma of smokers with and without chronic obstructive pulmonary disease (COPD): An exploratory analysis by next generation sequencing (NGS)
Human papillomavirus and non small cell lung cancer
Novel plasma circulating microRNA signature for early detection of non-small cell lung cancer in liquid biopsy
DNA methylation of SHOX2 and PTGER4 as a plasma-based tool to differentiate between patients with malignant and benign lung disease
Heterogeneity study of surgical treatment patterns among 11 medical centers of China in 2013 – a study of 2040 patients based on the Chinese national NSCLC outcome registry
Prognostic factors associated with lung cancer survival. A population-based study in the South of Spain
A retrospective analysis of the epidemiological and prognostic factors of non small cell lung cancer in an Egyptian tertiary referral center
Unemployment risk among lung cancer survivors: A population based study
Bronchial carcinoma in young people – Medical Oncology Department Experience
Domestic cooking fuel as a risk factor for lung cancer in women: A case control study
Overall survival in non-smokers and quitters compared to smokers who develop lung cancer: Case–control data from routine clinical practice
A tertiary care hospital based retrospective study evaluating epidemiology of lung cancers in a western state of India
A survey on smoking and tobacco control perceptions from physicians and employees working in an Italian cancer center
Analysis of penetration of smokeless tobacco forms using egg shell membrane as a substrate
Impact of legislative restrictions on tobacco usage in prevalence of COPD and other lung disorders in Kerala, India
Health care utilization and burden of lung cancer over the last decade: A nationwide analysis
Determination of care dependency in patients diagnosed with lung cancer and care burden in these patients' relatives
Economic evaluation of two therapeutic approaches in non small cell lung cancer
The Huaxi Emotional-Distress Index: An instrument for screening distress in Chinese inpatients with lung cancer
Self-reported depression among patients with non-small cell lung cancer
Determination of the association between continuous anger, anger expression and hope–hopelessness levels in patients with lung cancer
Accuracy of pleural fluid cytology in patients with malignant pleural effusion from non-small-cell lung cancer, pulmonary metastases and pleural mesothelioma. A case–control study
Accuracy of serum/pleural fluid lactate dehydrogenase ratio measurement in patients with malignant pleural effusion
Diagnostic value of carcinoembryonic antigen, lactate dehydrogenase and C-reactive protein in patients with pleural effusion undergoing VATS thoracentesis
Chromosomal aberrations in peripheral blood lymphocytes of lung cancer patients: A possible tool for early diagnosis
Transcutaneous electrical acupoint stimulation ameliorates chemotherapy-induced bone marrow suppression in lung cancer patients
Correlation of Raman and NIR spectroscopy for diagnosis of peripheral lung cancer
Development of a nanoformulation containing ganoderic acid for the prevention and treatment of the benzo[a]pyrene induced lung cancer
Incidence of glutathione S-transferase M1 and T1 polymorphisms among the smoker populations of Tabuk
Efficacy, safety and tolerability of MEDI4736 (durvalumab [D]), a human IgG1 anti-programmed cell death-ligand-1 (PD-L1) antibody, combined with gefitinib (G): A phase I expansion in TKI-naïve patients (pts) with EGFR mutant NSCLC
Association of EGFR mutation subtypes with clinical and demographic characteristics of patients (pts) with aNSCLC: IGNITE and ASSESS pooled analysis
Inhibition of pEGFR in paired tumour biopsies from TKI treatment-naïve EGFR mutant NSCLC patients treated with gefitinib (EGFR inhibitor) or gefitinib in combination with durvalumab (anti-PD-L1)
24h-blood profile gene expression biomarkers of the response to targeted therapy in advanced non-squamous non-small cell lung cancer (NSCLC)
Novel therapeutic strategies in NSCLC: Lung-tumorspheres as an effective in vitro screening platform
Molecular bases for combinatorial treatment strategies in KRAS mutant (KRASm) lung adenocarcinoma (LAC)
Identification of the functional significance of mutations using the novel Precision Cancer Analysis System
NEOliquid: Detection of KIF5B–RET fusions in liquid biopsy samples
Highly exhausted PD-1hi T cell subsets in human NSCLC are co-defined by the predominant expression of distinct inhibitory receptors and correlate with clinical outcome
Investigation of the interaction between non-small cell lung cancer cells and immortalised normal bronchial epithelial cells
Inflammatory meditated mechanisms of cisplatin resistance in non-small cell lung cancer
Effect of cigarette smoke exposure on anti-cancer activity of alveolar macrophage to Lewis lung carcinoma in mice
Identification of a novel microRNA signature: Potential diagnostic biomarkers and predictors of cisplatin response?
Exosomes isolated in plasma of non-small cell lung cancer patients contain microRNA related to the EGFR pathway: Proof of concept
Differential expression profile of lung squamous cell carcinoma (LSCC) cell lines as a mean to predict drug interaction effects
Generation of miR-21 sponges in lung cancer treatment
Elucidating drug resistance mechanisms using 2D and 3D culture systems
Inhibition and exploitation of aldehyde dehydrogenase 1 (ALDH1) as a cancer stem cell marker in cisplatin resistant NSCLC
An innovative co-targeting of signal transducer and activator of transcription 3 (STAT3) and Src-YAP pathways in EGFR mutant non-small cell lung cancer (NSCLC)
Glycolytic marker monocarboxylate transporter 4 (MCT4) and outcome to bevacizumab (bev): An exploratory analysis in advanced non-small cell lung cancer (A-NSCLC)
LCRMP-1 associated aptamers inhibit tumor metastasis
Tiechoic acids from Staphylococcus aureus enhance cytotoxic/cytostatic influence of bimetallic complex on primary tumor culture
XRCC6BP1: A key DNA repair gene in platinum-resistant NSCLC
Radiation resistance induced immunity evasion by evoking PD-L1 expression
Synergistic antitumor activity of afatinib and nintedanib through PP2A reactivation in non-small-cell lung cancer cells
Cerebral toxicity of whole brain radiotherapy plus icotinib in rats
Metabolic stress to sensitize non-small cell lung cancer (NSCLC) to radiotherapy: Studies from bench to bedside
Performance of EBUS-TBNA in NSCLC mediastinal staging stratified according to ACCP radiographic groups on CT
Correlation between invasive size and solid component on CT evaluated with various conditions, and their impact on tumor aggressiveness
Qualitative and quantitative interpretation of F-18 FDG PET/CT to differentiate metastatic mediastinal lymph node in non-small cell lung carcinoma patients with benign mediastinal lymph node hyperplasia
Use of brain imaging in the management of patients with lymph node negative multifocal lung cancer
Investigating the potential utility of the alternative IASLC nodal staging classification in NSCLC
Clinical validation of the M5L lung computer-assisted detection system
Validation of the 7th and upcoming 8th TNM staging system in small cell lung cancer
Validation of prognostic scores in small cell lung cancer
Chemoradiotherapy with radical intent for small cell lung cancer (SCLC): A 5 year retrospective review
First-line treatment with cisplatin plus etoposide for small cell lung cancer and large cell neuroendocrine carcinoma: Our center experience
The role of surgery in combination treatment of patients with small cell lung cancer
Small cell lung cancer: Prognostic factors and outcome at a tertiary care centre in South India
Overtreatment of patients with clinically diagnosed early stage lung cancer
Characterization of tumor infiltrating lymphocytes in resectable early stage non-small cell lung cancer
Modelling of pulmonary function test changes after stereotactic body radiotherapy for stage I NSCLC
Lymph node involvement influenced by lung adenocarcinoma subtypes in tumor size ≤3 cm disease: A study of 2268 cases
Preoperative nomogram for identifying invasive pulmonary adenocarcinoma in patients with pure ground-glass nodule: A multi-institutional study
Ablative robotic radiosurgery for inoperable patients with stage IA–IB non small cell lung cancer
Lobectomy for non-small cell lung cancer in octogenarians: A 7-year single center experience
Stereotactic body radiation therapy in early-stage non-small cell lung cancer in elderly patients: Safety and efficacy
Risk factors associated with symptomatic radiation pneumonitis after stereotactic body radiation therapy for stage I non-small cell lung cancer
Prognostic impact of incomplete interlober fissure in early stage lung cancer patients who underwent thoracoscopic lobectomy
A functional polymorphism located in intron of EGFR affects survival outcome of early-stage non-small cell lung cancer
Genetic polymorphisms in glycolytic pathway are associated with the prognosis of patients with early stage non-small cell lung cancer
ALK activates ERK5, in both neuroblastoma and lung cancer – a putative therapeutic target in cancer treatment
Predictive and prognostic role of T-regulatory cells in resected non-small cell lung cancer
Deltex-1 single nucleotide polymorphism rs1732786A>G is associated with the prognosis of surgically resected non-small cell lung cancer
Macrophage inhibitory cytokine-1 as a biomarker for diagnosis and prognosis of stage I–II non-small cell lung cancer
Enumeration and molecular characterization of circulating tumor cells in lung cancer patients using the GILUPI CellCollector
Expression analysis of tumorspheres from non-small cell lung cancer show significant differences in CSC-markers and signaling pathways
Brain metastases (BM) development after chemoradiation (CRT) for stage III non-small cell lung cancer (NSCLC): Does the type of chemotherapy matter?
Short-course, high-dose image-guided radiotherapy in poor risk patients with very central non-small cell lung cancer
Classification of EGFR mutations in Pakistani lung adenocarcinoma for predicting response to targeted therapy
PD-L1 expression as prognostic factor for survival after chemoradiotherapy of locally advanced NSCLC
Feasibility and efficacy of helical IMRT for stage III non-small cell lung cancer in comparison with conventionally fractionated 3D-CRT
Neoadjuvant chemotherapy followed by either continuous hyper-fractionated accelerated radiation therapy week-end less or conventional chemo-radiotherapy in locally advanced non small cell lung cancer
Survival following treatment of non-small cell lung cancer (NSCLC) using continuous hyperfractionated accelerated radiotherapy (CHART): A single-centre retrospective analysis
Concomitant chemo-radiation to 60 Gy followed by surgery for locally advanced non-small cell lung cancer patients; evaluation of trimodality strategy
Impact of the primary tumor metabolic volume (PT-MV) changes in the course of multimodality treatment on overall survival in patients with locally-advanced non-small cell lung cancer
Acute severe radiation pneumonitis in post-operation radiation therapy among patients with lung cancer: An analysis of dose-volume parameters
Comparison efficacy of preoperative chemotherapy and surgery with surgery alone in patients with stage IIIA non-small-cell lung cancer
Outcome after post-operative radiotherapy (PORT) in ypN2 or R1/R2 versus no PORT in ypN0 stage III-N2 non-small cell lung cancer after induction chemotherapy and resection
Maximum treatment response and prophylactic cranial irradiation are important prognostic factors in limited disease small-cell lung cancer patients comprehensively staged with cranial magnetic resonance imaging
Cryosurgery for advanced stages of non small cell lung cancer (5 years experience)
SAKK 16/14 – anti-PD-L1 antibody durvalumab (MEDI4736) in addition to neoadjuvant chemotherapy in patients with stage IIIA (N2) non-small cell lung cancer (NSCLC). A multicenter single-arm phase II trial
Efficacy and safety of BI 1482694 (HM61713), an EGFR mutant-specific inhibitor, in T790M-positive NSCLC at the recommended phase II dose
Combination of chemotherapy and gefitinib as first-line treatment of patients with advanced lung adenocarcinoma and sensitive EGFR mutations: A randomised controlled trial
Brigatinib efficacy and safety in patients (Pts) with anaplastic lymphoma kinase (ALK)-positive (ALK+) non-small cell lung cancer (NSCLC) in a phase 1/2 trial
Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trial
Nivolumab in patients (pts) with advanced refractory squamous (SQ) non-small cell lung cancer (NSCLC): 2-year follow-up from CheckMate 063 and exploratory cytokine profling analyses
Impact of dose adjustment on the safety and efficacy of afatinib in patients (pts) with advanced EGFR mutation-positive non-small cell lung cancer (NSCLC): Post-hoc analyses of LUX-Lung 3 (LL3) and LUX-Lung 6 (LL6)
Lifetime incidence of brain metastases (BM) in EGFR-mutant (M+) lung cancer treated with first-line EGFR TKIs
LUX-Lung 7: A Phase IIb, global, randomised, open-label trial of afatinib vs gefitinib as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) harbouring activating EGFR mutations
Whole body and intracranial efficacy of ceritinib in patients (pts) with crizotinib (CRZ) pretreated, ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) and baseline brain metastases (BM): Results from ASCEND-1 and ASCEND-2 trials
The impacts on work productivity from ceritinib compared with chemotherapy for crizotinib-experienced ALK+ non-small cell lung cancer
Bevacizumab and pemetrexed versus pemetrexed alone as maintenance therapy for patients with advanced nonsquamous NSCLC: Results of the expanded SAKK19/09 trial
Oligometastatic non-small-cell lung cancer (NSCLC) and unresectable primary tumor: Updated retrospective analysis of safety and efficacy of the radical treatment for the primary tumor and the metastases
Perspectives in oligometastatic brain lesions in non-small cell lung cancer (NSCLC)
The potential role for consolidative radiotherapy in oligometastatic non small cell lung cancer through the prism of pattern of failure analysis
Level of concordance between EGFR mutation status obtained from tissue/cytology and blood (plasma) for advanced non-small-cell lung cancer in Spain: ASSESS study
Concordance between detection of EGFR mutations on tissue and in circulating free tumor DNA (cftDNA) in newly diagnosed metastatic lung adenocarcinoma (mLA)
The role of CTCs and cfDNA for diagnosis and monitoring of EGFR mutations in advanced NSCLC patients
EGFR mutations in circulating tumor DNA (ctDNA) and tissue rebiopsy at progression on treatment with EGFR tyrosine kinase inhibitors (TKI)
Outcomes of research biopsies in clinical trials of EGFR mutation-positive NSCLC patients pretreated with EGFR-TKIs
The clinical utility of next-generation sequencing in lung cancer
Real-time PCR and digital PCR approach for detecting EGFR status in plasma of patients with NSCLC
Plasma dynamic monitoring of soluble c-Met level for EGFR-TKI treatment in advanced non-small cell lung cancer
PD-L1 polymorphism can predict clinical outcomes of non-small cell lung cancer patients treated with first-line paclitaxel–cisplatin chemotherapy
Correlation of baseline value of folate receptor-positive circulating tumor cells and efficacy of pemetrexed and dynamic monitoring study in NSCLC patients receiving first-line platinum-based chemotherapy
Serum tumor markers and the response to immunotherapy in advanced non-small cell lung carcinoma
PET/CT based imaging biomarkers for response prediction of stage IV NSCLC treated with paclitaxel–carboplatin–bevacizumab with or without nitroglycerin
Early radiological response (ERR) as predictor of overall survival in non small cell lung cancer (NSCLC) patients with EGFR mutations
Depressive symptoms, performance score, and personality traits as predictors of (health related) quality of life in patients with advanced stage lung cancer
Metabolic factors were associated with the outcome of gemcitabine-treated patients with advanced NSCLC identified by high through-put liquid-chip
Molecular markers in advanced non small cell lung cancer patients receiving gemcitabine & cisplatin
Prevalence of epidermal growth factor receptor (EGFR) gene mutations in non small cell lung cancer (NSCLC) in Bulgarian population
A review of prognostic factors for patients with epidermal growth factor receptor mutation positive advanced non small cell lung cancer (EGFR+NSCLC)
Long noncoding RNA LUCAT1 is associated with poor prognosis in human non-small cell lung cancer and affects cell proliferation via regulating p21 and p57 expression
Non-small cell lung cancer (NSCLC) patients with rare or complex epidermal growth factor receptor (EGFR) mutations: A single institution series
Efficacy of EGFR-TKIs for lung squamous carcinomas harboring EGFR mutation: A multicenter study and pooled analysis of published reports
Real life practice of gefitinib in patients (pts) with non-small-cell lung cancer (NSCLC) depending on epidermal growth factor receptor (EGFR) mutation status: Results from the prospective EPIDAURE study
Chemotherapy is not superior to erlotinib in pretreated patients with advanced non-small cell lung cancer (NSCLC): A retrospective study
Survival of lung adenocarcinoma patients with uncommon EGFR mutations in routine clinical practice in Slovenia
Carboplatin–paclitaxel bevacizumab followed by the addition of erlotinib to bevacizumab beyond progression in patients with advanced NSCLC
Antacid and de novo brain metastases in EGFR-mutant NSCLC patients treated with first-line, first-generation EGFR-TKIs
Vascular endothelial growth factor-C promotes EGFR-TKIs resistance and cancer stemness via SLUG of non-small cell lung cancer
Comparison of cardiovascular effects of crizotinib and chemotherapy in patients (pts) with ALK-positive (+) advanced non-small cell lung cancer (NSCLC)
ALK positive lung cancer: Clinical profile and outcomes in a developing country
ALK-rearranged non-small cell lung cancer is associated with a high rate of venous thromboembolism
Renal effects of crizotinib in patients (pts) with ALK-positive (+) advanced non-small cell lung cancer (NSCLC)
Continuation of ceritinib beyond disease progression is associated with prolonged post-progression survival (PPS) in ALK+ NSCLC
Nivolumab monotherapy in patients with previously treated advanced non-small cell lung cancer (NSCLC) in routine clinical practice in a Spanish center
Immunotherapy as an effective therapy approach for advanced non-small cell lung cancer (NSCLC): A single institution experience in the context of clinical trials and expanded access use
Anti-PD-1 antibodies in non-small cell lung cancer (NSCLC): The real-life setting experience
Intracranial response to nivolumab in NSCLC patients with untreated or progressing CNS metastases
Second-line treatment selection in patients with non-small cell lung cancer of adenocarcinoma histology: A European survey
The efficacy and safety of amrubicin in non-small-cell lung cancer patients beyond third-line therapy
Antiangiogenic therapy using bevacizumab in patients older than 75 years old with stage IV non-squamous non small cell lung cancer
Patient's feelings about side-effects are predictive for (Health Related) Quality of Life in patients with advanced stage lung cancer treated with chemotherapy
Palliative hypofractionated radiotherapy in south Egyptian patients with stage III and IV non-small cell lung cancer
Management of malignant pleural effusions
ELUXA 1: Phase II study of BI 1482694 (HM61713) in patients (pts) with T790M-positive non-small cell lung cancer (NSCLC) after treatment with an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI)
MYSTIC: a global, phase 3 study of durvalumab (MEDI4736) plus tremelimumab combination therapy or durvalumab monotherapy versus platinum-based chemotherapy (CT) in the first-line treatment of patients (pts) with advanced stage IV NSCLC
NEPTUNE: A global, phase 3 study of durvalumab (MEDI4736) plus tremelimumab combination therapy versus standard of care (SoC) platinum-based chemotherapy in the first-line treatment of patients (pts) with advanced or metastatic NSCLC
CheckMate 171: A multicenter phase 2 trial of nivolumab (nivo) in patients (pts) with stage IIIB/IV squamous cell (SQ) NSCLC who have received ≥1 prior systemic treatment
LUNAR: Phase III study of front-line chemotherapy with TTFields for advanced squamous NSCLC
Pembrolizumab (MK-3475) versus platinum-based chemotherapy for PD-L1+ NSCLC in a phase 3, randomized, open-label study: KEYNOTE-042
PREM-LC: Development and pilot testing of a patient reported experience measure in lung cancer
Identifying dosimetric predictors of toxicity in multiple lung tumors treated with stereotactic ablative radiotherapy (SABR)
Nomogram for predicting overall survival after stereotactic body radiotherapy for pulmonary metastases: Development and external validation
Which is the most common malignancy that profits from the lung metastasectomy? Ten years experience
Video-assisted thoracoscopic versus open pulmonary metastasectomy in patients with stage IV colorectal cancer and solitary lung metastasis. A preliminary case–control study and factors affecting survival
Pattern of metastases and their impact on outcomes in stage IV non small cell lung cancer – an institutional experience from South India
Could neutrophil-to-lymphocyte ratio be predictor of brain metastases in non small cell lung cancer?
Clinical value of CDX2 in the differential diagnosis of pulmonary adenocarcinoma from metastatic colorectal carcinoma
Visualizing ZO-1-mediated coupled migration between cancer and stromal cells in lung cancer metastasis via a 5-dimensional cell imaging system
METIS: A phase III study of radiosurgery with TTFields for 1–10 brain metastases from NSCLC
Extended pleurectomy decortication for malignant pleural mesothelioma in the elderly – the need for an inclusive yet selective approach
SMO mutation is a strong negative prognostic factor in malignant pleural mesothelioma
Digital gene expression profiling to separate malignant pleural mesothelioma from benign reactive mesothelial hyperplasia
Inflammatory cells characterization and localization in malignant pleural mesothelioma (MPM) tissue samples: Correlation with histologic subtype and prognosis
2nd line chemotherapy in malignant mesothelioma: A center's experience
Epithelial tumors of the thymus: Prognostic factors and multidisciplinary treatment
Correlation of thymoma with myasthenia gravis in ten years experience of their surgical treatment
STELLAR – A phase II trial of TTFields with chemotherapy for first line treatment of malignant mesothelioma
Clinical and demographic features that influence EGFR mutation detection in plasma from patients (pts) with aNSCLC: The ASSESS experience
Osimertinib as first-line treatment for EGFR mutation-positive advanced NSCLC: updated efficacy and safety results from two Phase I expansion cohorts
Osimertinib (AZD9291) in pre-treated pts with T790M-positive advanced NSCLC: updated Phase 1 (P1) and pooled Phase 2 (P2) results
Subgroup analyses of patients with epidermal growth factor receptor (EGFR)-expressing tumors in SQUIRE: A randomized, multicenter, open-label, phase III study of gemcitabine–cisplatin (GC) plus necitumumab (N) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC)
Plasma ctDNA analysis for detection of EGFR T790M mutation in patients (pts) with EGFR mutation-positive advanced non-small cell lung cancer (aNSCLC)
Plasma genotyping for predicting benefit from osimertinib in patients (pts) with advanced NSCLC
nab-Paclitaxel + carboplatin (nab-P/C) in advanced non-small cell lung cancer (NSCLC): outcomes in elderly patients (pts) with squamous (SCC) histology
CRS-207 with chemotherapy (chemo) in malignant pleural mesothelioma (MPM): Results from a phase 1b trial